Corcept therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Corcept therapeutics Contact Number

SRO List Detail

6 hours ago Accessdata.fda.gov Get All

DUNS NUMBER: 069540610 BUSINESS NAME: Corcept Therapeutics Incorporated COUNTRY NAME: USA TICKER SYMBOL:

Website: https://www.accessdata.fda.gov/scripts/sda/sdDetailNavigation.cfm?sd=srolist&id=C54903A68BEE066BE0530D98C30AC62A

Category: Contact NumberShow more

Corcept Therapeutics (CORT) Company Profile & Overview

6 hours ago Stockanalysis.com Get All

Company profile for Corcept Therapeutics, including a description, list of executives, contact details and other key facts. Company profile for Corcept Therapeutics, including a description, list of executives, contact details and other key facts. CUSIP Number: 218352102: ISIN Number: US2183521028: Employer ID: 77-0487658: Key Executives

Website: https://stockanalysis.com/stocks/cort/company/

Category: Contact NumberShow more

Corcept Announces Presentation of Positive Results From

6 hours ago Ir.corcept.com Get All

Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021; Results show benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept’s proprietary selective cortisol modulator, relacorilant

Website: https://ir.corcept.com/news-releases/news-release-details/corcept-announces-presentation-positive-results-randomized

Category: Contact NumberShow more

Corcept Announces Presentation of Positive Results From

2 hours ago Globenewswire.com Get All

Presentation Number: 721O. About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and

Website: https://www.globenewswire.com/news-release/2021/09/09/2294773/0/en/Corcept-Announces-Presentation-of-Positive-Results-From-Randomized-Controlled-Phase-2-Trial-of-Relacorilant-in-Patients-With-Recurrent-Platinum-Resistant-Ovarian-Cancer-at-ESMO-202.html

Category: Contact NumberShow more

Corcept Therapeutics Incorporated Common Stock (CORT

Just Now Nasdaq.com Get All

Corcept Therapeutics Incorporated Common Stock including the number of shares held by those institutions in a firm, along with recent purchases and sales information. Contact Careers

Website: https://www.nasdaq.com/market-activity/stocks/cort/institutional-holdings?16699=

Category: Contact NumberShow more

CORT: Corcept Therapeutics Incorporated Full Company

7 hours ago Zacks.com Get All

CORT: Corcept Therapeutics Incorporated - Full Company Report. Get the latest Full Company Report for Corcept Therapeutics Incorporated from Zacks Investment Research

Website: https://www.zacks.com/stock/research/CORT/company-reports

Category: Contact NumberShow more

Insider Trading Transactions at Corcept Therapeutics Inc

3 hours ago Form4oracle.com Get All

Corcept Therapeutics Inc. (CORT) 01-Sep-21: Market Option Sale (Planned) 25,000: $21.40: $534,930.00 (29%) 85.02K to 60.02K: 03-Sep-21 10:00 PM View: Maduck Sean Chief Commercial Officer: Corcept Therapeutics Inc. (CORT) 01-Sep-21: Option Exercise : 25,000: $3.29: $82,250.00: 42% 60.02K to 85.02K: 01-Sep-21 5:36 PM View: Robb Gary Charles Chief

Website: http://www.form4oracle.com/company/corcept-therapeutics-inc-cort/company-transactions?id=8156

Category: Contact NumberShow more

Corcept Announces Presentation of Positive Results From

8 hours ago Yahoo.com Get All

CONTACT: Corcept Therapeutics Investor Relations [email protected]corcept.com 2021--An increasing number of broadcasters and channel operators worldwide are adopting SES’s Cloud Playout service to better

Website: https://www.yahoo.com/now/corcept-announces-presentation-positive-results-200500882.html

Category: Contact NumberShow more

Corcept (CORT) falls 1.14% to Close at $20.86 on September

7 hours ago Equities.com Get All

Corcept Therapeutics Inc (NASDAQ: CORT), a Menlo Park, California, company, fell to close at $20.86 Monday after losing $0.24 (1.14%) on volume of 434,636 shares. The stock ranged from a high of

Website: https://www.equities.com/news/corcept-cort-falls-1-14-to-close-at-20-86-on-september-13

Category: Contact NumberShow more

Hancock Whitney Corp Has $573,000 Holdings in Corcept

3 hours ago Mayfieldrecorder.com Get All

Hancock Whitney Corp lessened its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 23.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,029 shares of the biotechnology company’s stock after selling 7,755 shares during the quarter. Hancock Whitney Corp’s holdings in Corcept Therapeutics were worth […]

Website: https://mayfieldrecorder.com/2021/09/11/hancock-whitney-corp-has-573000-holdings-in-corcept-therapeutics-incorporated-nasdaqcort.html

Category: Contact NumberShow more

Corcept Announces Presentation of Positive Results From

8 hours ago Sg.news.yahoo.com Get All

Corcept Therapeutics Incorporated 9 September 2021, 4:05 pm · 3-min read Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021

Website: https://sg.news.yahoo.com/corcept-announces-presentation-positive-results-200500882.html

Category: Contact NumberShow more

Corcept Therapeutics (CORT) Announces Results from Phase 2

4 hours ago Streetinsider.com Get All

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by

Website: https://www.streetinsider.com/Corporate+News/Corcept+Therapeutics+%28CORT%29+Announces+Results+from+Phase+2+Trial+of+Relacorilant+in+Patients+with+Recurrent+Platinum-Resistant+Ovarian+Cancer/18952545.html

Category: Contact NumberShow more

Scrip

8 hours ago Scrip.pharmaintelligence.informa.com Get All

(212) 520-2765Please contact Sales at: (212) 520-2765 or email [email protected] Latest From Corcept Therapeutics Incorporated Future Of Surgery: Virtual Reality, Robotics And Collaboration

Website: https://scrip.pharmaintelligence.informa.com/companies/720

Category: Contact NumberShow more

Corcept Therapeutics Inc, CORT:NAQ profile FT.com

5 hours ago Markets.ft.com Get All

Year on year Corcept Therapeutics Inc grew revenues 15.46% from 306.49m to 353.87m while net income improved 12.56% from 94.18m to 106.01m. View all financials Explore our tools

Website: https://markets.ft.com/data/equities/tearsheet/profile?s=CORT:NAQ

Category: Contact NumberShow more

Corcept Therapeutics Inc, CORT:DEU profile FT.com

5 hours ago Markets.ft.com Get All

Year on year Corcept Therapeutics Inc grew revenues 15.46% from 306.49m to 353.87m while net income improved 12.56% from 94.18m to 106.01m. View all financials

Website: https://markets.ft.com/data/equities/tearsheet/profile?s=CORT:DEU

Category: Contact NumberShow more

Corcept Announces Presentation of Positive Results From

6 hours ago Ca.finance.yahoo.com Get All

Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021Results show benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept’s proprietary selective cortisol modulator, relacorilant MENLO PARK

Website: https://ca.finance.yahoo.com/news/corcept-announces-presentation-positive-results-200500882.html

Category: Contact NumberShow more

Corcept Announces Presentation GuruFocus.com

Just Now Gurufocus.com Get All

GuruFocus Article or News written by Marketwired and the topic is about:

Website: https://www.gurufocus.com/news/1520590/corcept-announces-presentation-of-positive-results-from--randomized-controlled-phase-2-trial-of-relacorilant-in-patients-with-recurrent-platinumresistant-ovarian-cancer-at-esmo-2021

Category: Contact NumberShow more

Corcept Therapeutics Presents Positive Results From Phase

8 hours ago Markets.businessinsider.com Get All

Corcept Therapeutics EPS beats by $0.13, beats on revenue Seeking Alpha 50d The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs

Website: https://markets.businessinsider.com/news/stocks/corcept-therapeutics-presents-positive-results-from-phase-2-trial-of-relacorilant-on-ovarian-cancer-1030807339

Category: Contact NumberShow more

Corcept Announces Presentation of Positive Results From

Just Now Marketscreener.com Get All

MENLO PARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that results from its 178-patient, randomized

Website: https://www.marketscreener.com/quote/stock/CORCEPT-THERAPEUTICS-INCO-40449488/news/Corcept-Announces-Presentation-of-Positive-Results-From-Randomized-Controlled-Phase-2-Trial-of-Re-36389041/

Category: Contact NumberShow more

Corcept Therapeutics Incorporated (CORT) Stock Price Today

6 hours ago Seekingalpha.com Get All

A high-level overview of Corcept Therapeutics Incorporated (CORT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Website: https://seekingalpha.com/symbol/CORT

Category: Contact NumberShow more

Corcept Announces Presentation of Positive Results From

2 hours ago Newsazi.com Get All

Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021 Results show benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept’s proprietary selective cortisol modulator, relacorilant MENLO PARK

Website: https://newsazi.com/corcept-announces-presentation-of-positive-results-from-randomized-controlled-phase-2-trial-of-relacorilant-in-patients-with-recurrent-platinum-resistant-ovarian-cancer-at-esmo-2021/

Category: Contact NumberShow more

Corcept Therapeutics (CORT) Stock Price, Quote & News

8 hours ago Stockanalysis.com Get All

Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results. MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in …

Website: https://stockanalysis.com/stocks/cort/

Category: Contact NumberShow more

https://research.investors.com/stockquotes/nasdaqcorcept

8 hours ago Bepanahpeyar.com Get All

July 16, 2021 Who Is Matthew Underwood Related To Carrie Underwood To Carrie Underwood? July 16, 2021 Kid Cudi Inspirational Quotes By Kid Cudi (Of 103), Top 25 Quotes By Kid Cudi (Of 103)

Website: https://bepanahpeyar.com/https-research-investors-com-stock-quotes-nasdaq-corcept-therapeutics-inc-cort-htm/

Category: Contact NumberShow more

Is Corcept Therapeutics Incorporated (CORT) Stock Trading

4 hours ago Investorsobserver.com Get All

Corcept Therapeutics Incorporated ( CORT) receives a strong valuation ranking of 63 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. CORT has a better value than 63% of stocks based on these valuation analytics.

Website: https://www.investorsobserver.com/news/stock-update/is-corcept-therapeutics-incorporated-cort-stock-trading-below-fair-value

Category: Contact NumberShow more

OTC Dynamics $CORT Corcept Announces Presentation of

5 hours ago Otcdynamics.com Get All

on September 9, 2021 News and Tags: Corcept Therapeutics Inc., Corcept Therapeutics Inc. News, CORT, CORT News with 0 comments Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at …

Website: https://www.otcdynamics.com/cort-corcept-announces-presentation-of-positive-results-from-randomized-controlled-phase-2-trial-of-relacorilant-in-patients-with-recurrent-platinum-resistant-ovarian-cancer-at-esmo-2021/

Category: Contact NumberShow more

Corcept Therapeutics Incorporated (NASDAQ: CORT) Investing

6 hours ago Marketingsentinel.com Get All

During the last session, Corcept Therapeutics Incorporated (NASDAQ:CORT)’s traded shares were 0.4 million, with the beta value of the company hitting 0.68. At the end of the trading day, the stock’s price was $21.53, reflecting an intraday loss of -0.87% or -$0.19. The 52-week high for t

Website: https://marketingsentinel.com/2021/09/04/corcept-therapeutics-incorporated-nasdaq-cort-investing-potential-is-21-53/

Category: Contact NumberShow more

CORT: Corcept Therapeutics Inc Stock Price, Quote and

2 hours ago Cnbc.com Get All

Get Corcept Therapeutics Inc (CORT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Website: https://www.cnbc.com/quotes/CORT

Category: Contact NumberShow more

$97.75 Million in Sales Expected for Corcept Therapeutics

7 hours ago Marketbeat.com Get All

Corcept Therapeutics has a 1-year low of $12.81 and a 1-year high of $31.18. About Corcept Therapeutics. Corcept Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders.

Website: https://www.marketbeat.com/instant-alerts/nasdaq-cort-consensus-analyst-rating-2021-09/

Category: Contact NumberShow more

Corcept Announces Presentation of Positive Results From

3 hours ago Wallstbusinessnews.com Get All

MENLO PARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that results from its 178-patient, randomized

Website: https://wallstbusinessnews.com/corcept-announces-presentation-of-positive-results-from-randomized-controlled-phase-2-trial-of-relacorilant-in-patients-with-recurrent-platinum-resistant-ovarian-cancer-at-esmo-2021/

Category: Contact NumberShow more

Dividend History Corcept Therapeutics Incorporated (CORT

8 hours ago Zacks.com Get All

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst

Website: https://www.zacks.com/stock/research/CORT/dividend-history

Category: Contact NumberShow more

Corcept Therapeutics Incorporated CORT Stock Quotes and

9 hours ago M.insidertracking.com Get All

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the

Website: https://m.insidertracking.com/company?ticker=CORT

Category: Contact NumberShow more

Positive Results Presented at ESMO 2021 From Randomized

2 hours ago Finance.yahoo.com Get All

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Robb sold 55,000 shares of Corcept Therapeutics

Website: https://finance.yahoo.com/news/positive-results-presented-esmo-2021-123000002.html

Category: Contact NumberShow more

Company Fundamentals

6 hours ago Research.tdameritrade.com Get All

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the

Website: https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol=CORT

Category: Contact NumberShow more

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB

3 hours ago Benzinga.com Get All

Corcept Therapeutics Incorporated (NASDAQ: CORT) said positive results from its 178-patient, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian

Website: https://www.benzinga.com/general/biotech/21/09/22882566/the-daily-biotech-pulse-apellis-sinks-on-data-endo-shines-on-opioid-litigation-settlement-t2-bios

Category: Tech SupportShow more

Calliditas FDA Decision, Adcom Review for Pfizer

7 hours ago Journal-beat.com Get All

Biotech stocks fell back in the holiday shortened week that ended on September 10, reversing the course of the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest declines for the week after the company said the Food and Drug Administration refused to authorize its COVID-19 treatment for emergency use. Mersana Therapeutics, Inc. (MRSN) […]

Website: https://journal-beat.com/calliditas-fda-decision-adcom-review-for-pfizer-biontech-covid-19-vaccine-oncology-conference-and-ipo/

Category: Contact NumberShow more

SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU

1 hours ago Greenstocknews.com Get All

National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Odonate Therapeutics, Inc., Aytu Biopharma, Inc., Eargo, Inc., and Corcept Therapeutics, Inc. If you are a current owner of shares of any of these stocks, contact This …

Website: https://greenstocknews.com/news/nasdaq/aytu/shareholder-alert-morris-kandinov-investigating-odt-aytu-ear-and-cort-shareholders-are-encouraged-to-contact-the-firm

Category: Contact NumberShow more

Zillow Group And 6 Other Stocks Have High Sales Growth And

6 hours ago Via.news Get All

Corcept Therapeutics Incorporated’s stock is valued at $20.60 at 01:22 EST, way under its 52-week high of $31.18 and way higher than its 52-week low of $16.42. Corcept Therapeutics Incorporated’s Moving Average. Corcept Therapeutics Incorporated’s worth is under its 50-day moving average of $21.01 and under its 200-day moving average of

Website: https://via.news/markets/zillow-group-6-other-stocks-high-sales-growth-an-above-3-return-equity/

Category: Contact NumberShow more

The Daily Biotech Pulse: Apellis Sinks On Data, Endo

Just Now Markets.businessinsider.com Get All

Adagio Therapeutics, Inc. (NASDAQ:ADGI) Axonics, Inc which is 40% of the total number of patients to be enrolled in the trial, the company said. Corcept To Present Positive Mid-stage

Website: https://markets.businessinsider.com/news/stocks/the-daily-biotech-pulse-apellis-sinks-on-data-endo-shines-on-opioid-litigation-settlement-t2-biosystems-soars-on-mutant-detection-ability-of-covid-test-1030792468

Category: Tech SupportShow more

Corcept Therapeutics Incorporated : Positive Results

Just Now Marketscreener.com Get All

CONTACT: Corcept Therapeutics Investor Relations [email protected]corcept.com www.corcept.com. Source: Corcept Therapeutics Incorporated. Number of Analysts: 4: Last Close Price: 20,63 $ Average target price: 25,25 $ Spread / Average Target: 22,4%: Consensus. EPS Revisions More Estimates Revisions

Website: https://www.marketscreener.com/quote/stock/CORCEPT-THERAPEUTICS-INCO-40449488/news/Corcept-Therapeutics-Incorporated-Positive-Results-Presented-at-ESMO-2021-From-Randomized-Control-36451854/

Category: Contact NumberShow more

Corcept Announces Presentation of Positive Results From

3 hours ago Chat-beta.ceo.ca Get All

MENLO PARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that results from its 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus

Website: https://chat-beta.ceo.ca/@nasdaq/corcept-announces-presentation-of-positive-results

Category: Contact NumberShow more

Zacks: Brokerages Expect Corcept Therapeutics Incorporated

1 hours ago Marketbeat.com Get All

Equities analysts expect that Corcept Therapeutics Incorporated (NASDAQ:CORT) will announce $0.19 earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Corcept Therapeutics' earnings, with estimates ranging from $0.18 to $0.21. Corcept Therapeutics

Website: https://www.marketbeat.com/instant-alerts/nasdaq-cort-consensus-analyst-rating-2021-09-2-3/

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Cisco
Costco
Cae
Ccu
Crh
Cameco
Cerner